These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28267447)

  • 1. Potential Issues With the Handling of Biologicals in a Hospital.
    Jiskoot W; Nejadnik MR; Sediq AS
    J Pharm Sci; 2017 Jun; 106(6):1688-1689. PubMed ID: 28267447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On prilling of hydrophilic microgels in lipid dispersions using mono-N-carboxymethyl chitosan for oral biologicals delivery.
    De Kruif JK; Fasler-Kan E; Varum F; Bravo R; Kuentz M
    J Pharm Sci; 2014 Nov; 103(11):3675-3687. PubMed ID: 25241928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues.
    Nejadnik MR; Randolph TW; Volkin DB; Schöneich C; Carpenter JF; Crommelin DJA; Jiskoot W
    J Pharm Sci; 2018 Aug; 107(8):2013-2019. PubMed ID: 29665382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb.
    Gruia F; Du J; Santacroce PV; Remmele RL; Bee JS
    J Pharm Sci; 2015 Apr; 104(4):1539-42. PubMed ID: 25270279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of biotechnology products.
    Tami J; Evens RP
    Pharmacotherapy; 1996; 16(4):527-36. PubMed ID: 8840359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Formulation and Delivery of Biologics.
    Besheer A; Mahler HC
    Pharm Res; 2020 Oct; 37(11):225. PubMed ID: 33078256
    [No Abstract]   [Full Text] [Related]  

  • 7. CMC determination of nonionic surfactants in protein formulations using ultrasonic resonance technology.
    Horiuchi S; Winter G
    Eur J Pharm Biopharm; 2015 May; 92():8-14. PubMed ID: 25684280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and Stability of Solutions.
    Akers MJ
    Int J Pharm Compd; 2016; 20(2):137-41. PubMed ID: 27326440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Closed System Transfer Device (CSTD) Handling Procedure for Low-Transfer-Volume Dose Preparation of Biologic Drug Products.
    Grzincic EM; Parikh T; Hong C; Rabiah NI; Yi L; Gupta S
    J Pharm Sci; 2024 Jun; 113(6):1523-1535. PubMed ID: 38142969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of temperature-controlled requirements into pharmacy practice.
    Ziance R; Chandler C; Bishara RH
    J Am Pharm Assoc (2003); 2009; 49(3):e61-7; quiz e68-9. PubMed ID: 19443313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advice of manufacturers about effects of temperature on biologicals.
    Miller LG; Loomis JH
    Am J Hosp Pharm; 1985 Apr; 42(4):843-8. PubMed ID: 4014237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Storage and handling of biotech agents.
    Piascik P
    Am Pharm; 1994 Aug; NS34(8):22-3, 28. PubMed ID: 7942496
    [No Abstract]   [Full Text] [Related]  

  • 14. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals.
    Crawford SY; Narducci WA; Augustine SC
    Am J Hosp Pharm; 1991 Nov; 48(11):2398-413. PubMed ID: 1746573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discontinuation of biologicals in rheumatoid arthritis after acquiring remission? No].
    Grünke M
    Dtsch Med Wochenschr; 2011 Aug; 136(33):1675. PubMed ID: 21833890
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of 2-D DIGE to survey the quality of biological medicines.
    Miller I; Gemeiner M; Göstl G; Weber A; Unkelbach U; Beck G; Lackner F
    Proteomics; 2011 May; 11(10):2120-3. PubMed ID: 21462342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.
    Calvo-Alén J; Monteagudo I; Salvador G; Vázquez-Rodríguez TR; Tovar-Beltrán JV; Vela P; Maceiras F; Bustabad S; Román-Ivorra JA; Díaz-Miguel C; Rosas J; Raya E; Carmona L; Cea-Calvo L; Arteaga MJ; Fernández S; Marras C
    Clin Exp Rheumatol; 2017; 35(3):423-430. PubMed ID: 28032846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic stability: an issue of product quality.
    Burns N
    Biologicals; 1993 Jun; 21(2):145-6. PubMed ID: 8297594
    [No Abstract]   [Full Text] [Related]  

  • 20. Formulation and Delivery of Macromolecules.
    Morales JO
    AAPS PharmSciTech; 2017 Jan; 18(1):1-2. PubMed ID: 27943123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.